ADMA metabolism and clearance
- PMID: 16444872
- DOI: 10.1191/1358863x05vm597oa
ADMA metabolism and clearance
Abstract
The plasma concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is the resultant of many processes at cellular and organ levels. Post-translational methylation of arginine residues of proteins plays a crucial role in the regulation of their functions, which include processes such as transcription, translation and RNA splicing. Because protein methylation is irreversible, the methylation signal can be turned off only by proteolysis of the entire protein. Consequently, most methylated proteins have high turnover rates. Free ADMA, which is formed during proteolysis, is actively degraded by the intracellular enzyme dimethylarginine dimethylaminohydrolase (DDAH). Some ADMA escapes degradation and leaves the cell via cationic amino acid transporters. These transporters also mediate uptake of ADMA by neighboring cells or distant organs, thereby facilitating active interorgan transport. Clearance of ADMA from the plasma occurs in small part by urinary excretion, but the bulk of ADMA is degraded by intracellular DDAH, after uptake from the circulation. This review discusses the various processes involved in ADMA metabolism: protein methylation, proteolysis of methylated proteins, metabolism by DDAH, and interorgan transport. In addition, the role of the kidney and the liver in the clearance of ADMA is highlighted.
Similar articles
-
Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness.Metabolism. 2012 Apr;61(4):482-90. doi: 10.1016/j.metabol.2011.08.007. Epub 2011 Oct 13. Metabolism. 2012. PMID: 22000584
-
Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.Transl Res. 2013 Aug;162(2):67-76. doi: 10.1016/j.trsl.2013.04.005. Epub 2013 May 22. Transl Res. 2013. PMID: 23707198
-
Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.J Am Soc Nephrol. 2006 Aug;17(8):2176-83. doi: 10.1681/ASN.2005121379. Epub 2006 Jun 28. J Am Soc Nephrol. 2006. PMID: 16807406
-
The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.Nat Rev Drug Discov. 2011 Apr;10(4):277-91. doi: 10.1038/nrd3358. Nat Rev Drug Discov. 2011. PMID: 21455237 Review.
-
The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.JPEN J Parenter Enteral Nutr. 2008 Nov-Dec;32(6):613-21. doi: 10.1177/0148607108321702. JPEN J Parenter Enteral Nutr. 2008. PMID: 18974239 Review.
Cited by
-
Protein Arginine Methyltransferases (PRMTs): promising targets for the treatment of pulmonary disorders.Int J Mol Sci. 2012 Sep 27;13(10):12383-400. doi: 10.3390/ijms131012383. Int J Mol Sci. 2012. PMID: 23202904 Free PMC article. Review.
-
The Relationship of Left Ventricular Diastolic Dysfunction and Asymmetrical Dimethylarginine as a Biomarker of Endothelial Dysfunction with Cardiovascular Risk Assessed by Systematic Coronary Risk Evaluation2 Algorithm and Heart Failure-A Cross-Sectional Study.Int J Environ Res Public Health. 2023 Mar 1;20(5):4433. doi: 10.3390/ijerph20054433. Int J Environ Res Public Health. 2023. PMID: 36901443 Free PMC article.
-
The influence of different diets on metabolism and atherosclerosis processes-A porcine model: Blood serum, urine and tissues 1H NMR metabolomics targeted analysis.PLoS One. 2017 Oct 9;12(10):e0184798. doi: 10.1371/journal.pone.0184798. eCollection 2017. PLoS One. 2017. PMID: 28991897 Free PMC article.
-
A Recombinant Dimethylarginine Dimethylaminohydrolase-1-Based Biotherapeutics to Pharmacologically Lower Asymmetric Dimethyl Arginine, thus Improving Postischemic Cardiac Function and Cardiomyocyte Mitochondrial Activity.Mol Pharmacol. 2022 Apr;101(4):226-235. doi: 10.1124/molpharm.121.000394. Epub 2022 Jan 18. Mol Pharmacol. 2022. PMID: 35042831 Free PMC article.
-
Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine.J Pharmacol Exp Ther. 2009 Oct;331(1):234-43. doi: 10.1124/jpet.109.153510. Epub 2009 Jul 15. J Pharmacol Exp Ther. 2009. PMID: 19605523 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources